Article
Trump's Tariff Wall Returns With Forced-Labor Duties On 60 Countries
aboutLiberty Portal
Liberty Portal is your gateway for free markets and free thinking. We aggregate open-sourced content to promote and popularize important people and lessons within the liberty movement.
suggested
Apr 30, 2026 / Tyler Durden
Welcome To Another Diverse Day In The UK...
Welcome To Another Diverse Day In The UK...
Authored by Steve Watson via Modernity.news,
Two shocking incidents unfolding on the same day lay bare the consequences of unchecked mass immigration and a multiculturalism experiment gone wrong in Britain.
In Crewe, police mounted a massive raid on an Islamic sect accused of running a compound rife with modern slavery, forced marriages, and sexual abuse.
Meanwhile, in London, a knife-wielding attacker stabbed two Jewish men in a brazen assault now treated as terrorism. Yet amid the chaos, some voices seem more outraged by police using...
Read more
May 22, 2026 / Tyler Durden
Singham Network Mobilizes To Defend Raúl Castro After DOJ Indictment
Singham Network Mobilizes To Defend Raúl Castro After DOJ Indictment
Via American Greatness,
Key organizations and activists tied to the CCP-linked Singham Network rapidly moved to defend former Cuban dictator Raúl Castro following this week’s Justice Department indictment tied to the 1996 shootdown of civilian aircraft flown by Brothers to the Rescue.
The indictment, unveiled by the United States Department of Justice, charges Castro and others in connection with the deaths of four men after Cuban MiG fighter jets destroyed two civilian planes over international waters near Cuba nearly three decades ago. Prosecutors said the...
Read more
Aug 5, 2026 / Tyler Durden
"Momentum Continues": Lilly Jumps After Raising Revenue Outlook On Surging GLP-1 Demand
"Momentum Continues": Lilly Jumps After Raising Revenue Outlook On Surging GLP-1 Demand
Shares of Eli Lilly & Co. are rising in premarket trading after the pharmaceutical giant raised its full-year revenue forecast following a 48% jump in second-quarter sales, fueled by accelerating demand for the diabetes drug Mounjaro and the obesity treatment Zepbound.
Lilly's second-quarter results topped Wall Street expectations: Adjusted earnings rose to $8.38 a share from $6.31 a year earlier. Revenue surged 48% to $22.97 billion, beating the $20.59 billion Bloomberg Consensus estimate.
Mounjaro generated $9.94 billion in sales, exceeding...
Read more




